MONMOUTH JUNCTION, N.J., Oct 04, 2012 (BUSINESS WIRE) -- TYRX, Inc., the leader in the commercialization of implantable medical devices intended to help reduce surgical site infections, announced today that it has received a license from Health Canada to market its AIGISRx Antibacterial Envelope. The AIGISRx Envelope is specifically designed to stabilize pacemakers and implantable defibrillators while also releasing antimicrobial agents to help provide protection from microbial colonization of the device during surgical implantation.
TYRX(R) Receives Health Canada Approval
FierceMedicalDevices Names TYRX® as one of its “Fierce 15” Medical Device and Diagnostic Companies of 2012
Monmouth Junction, NJ – (October 2, 2012) – TYRX, Inc. announced today that it has been named to the FierceMedicalDevices “Fierce 15” list, designating it as one of the leading medical device and diagnostic companies of 2012.
FierceMedicalDevices Editors Mark Hollmer and Damian Garde, in conjunction with Editor-in-Chief John Carroll and Executive Editor Ryan McBride, chose this year's winners based on their top management teams, notable financial backing, and promising technologies and market opportunities. TYRX was chosen as one of the Fierce 15 based, in part, on its creativity and innovations in the industry.
TYRX® Comments on Medicare Decision to Stop Paying for Infections Following Pacemaker or Defibrillator Implants Release
Monmouth Junction, NJ (August 2, 2012) - In a bid to help control health care costs, on October 1, 2012, the Centers for Medicare and Medicaid Services (CMS) will stop paying hospitals for treating potentially avoidable surgical site infections following Cardiac Implantable Electronic Device (CIED) procedures including pacemaker and defibrillator implants. CMS just released its Hospital Inpatient Prospective Payment System (IPPS) Final Rule for Fiscal Year 2013 which adds Surgical Site Infection following CIED implantation as a condition subject to the Hospital Acquired Condition payment provision. CMS considers these infections to be reasonably preventable and has classified them as complicating conditions that would otherwise result in higher payment to the hospital. Under the new policy, CMS will pay for the original surgery, but will not reimburse hospitals at a higher rate for treating the infection.
TYRX, Inc. raises $20 million in private financing
Proceeds will Support Continued Commercialization of the AIGISRx® Antibacterial Envelope and Development of Next Generation Products
Monmouth Junction, NJ (December 8, 2010) – TYRX, Inc., the leader in the commercialization of implantable medical devices designed to help reduce surgical-site infections associated with implantable pacemakers and defibrillators, announced today that it has raised $20 million in venture capital funding. The funding was led by new investor, HLM Venture Partners along with previous investors Clarus Ventures and Pappas Ventures. The financing round also included $4 million in debt financing from Comerica Bank. In connection with the financing, Edward L. Cahill, Managing Partner, HLM Venture Partners, will join TYRX’s Board of Directors.
FDA provides clearance of TyRx antibacterial patch for soft tissue repair
MONMOUTH JUNCTION, N.J., April 27, 2010 --(BUSINESS WIRE)-- TYRX, Inc. announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market AIGISRx® ST , its antibacterial product for the surgical repair of damaged or ruptured soft tissue.
TYRX had previously received 510(k) clearance to market a product for hernia repair and other abdominal soft tissue deficiencies. The new clearance adds the use as a soft tissue patch to reinforce soft tissue where weakness exists and for the surgical repair of damaged or ruptured soft tissue. AIGISRx ST delivers the antimicrobial agents, rifampin and minocycline. These antimicrobial agents have been shown to reduce infections associated with medical devices in multiple randomized controlled trials.
New Anti-Bacterial Device Helps Reduce Infections Associated with Pacemaker and Defibrillator Implantation
Monmouth Junction, NJ, (April 13, 2010) -- TYRX, Inc. announced today the commercial release of the AIGISRx® Flat, an antibacterial product that helps provide protection against infections associated with implanted pacemakers and defibrillators.
Like the original AIGISRx™ Envelope, AIGISRx Flat delivers the anti-microbial agents, rifampin and minocycline which have been shown to reduce infection by organisms representing a majority of the infections reported in cardiac rhythm management device (CRMD)-related endocarditis, including “superbugs” or MRSA. AIGISRx Flat also offers the implanting physician additional flexibility in the application of these lifesaving devices.
TyRx enrolls first patient in CITADEL study for AIGISRx™ anti-bacterial envelope with ICD replacements
MONMOUTH JUNCTION, N.J., March 24, 2010--(EON: Enhanced Online News) - TYRX, Inc., a leader in the commercialization of implantable medical devices designed to help reduce infection, announced today that it has begun enrollment in CITADEL, the second of two large scale, prospective, multicenter studies.
Tyrx presents early clinical results from AIGISRXTM antibacterial envelope retrospective registry
Monmouth, NJ, (May 22, 2009) -- TYRX, Inc., a leader in the commercialization of implantable medical-pharmaceutical devices announced today at the 30th Annual Scientific Sessions of the Heart Rhythm Society the initial, interim clinical results from its AIGISRXTM Antibacterial Envelope Retrospective Registry.
TyRx Pharma raises $25 million
Proceeds Will Support Commercialization of the AIGISrx™ CRMD AntiBacterial Envelope and Development and Launch of Additional Drug-Eluting Devices in the TyRx Pipeline
Monmouth Junction, NJ, (February 27, 2008) -- TyRx Pharma, Inc., a leader in the commercialization of implantable combination drug-device products, announced today that the Company has raised $25 million in a venture capital financing led by Clarus Ventures and co-led by Pappas Ventures. In connection with the financing, Jeffrey Leiden, M.D., Ph.D., Managing Director, and Scott Requadt, J.D., MBA, Principal, both of Clarus Ventures, and Arthur Pappas, Managing Partner, Pappas Ventures, will join TyRx's Board of Directors.
